In examining recent analyst actions, we gain insights into how financial experts perceive Eli Lilly. The following summary outlines key analysts, their recent evaluations, and adjustments to ...

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

Eli Lilly is vulnerable to them. That being said, the analyst was clearly impressed by the company's momentum with Zepbound. His research indicates that it's notably pulling ahead of Novo Nordisk ...

Eli Lilly (NYSE:LLY) harnessed significant operational performance during the latest quarter, reporting robust sales and net ...

Bernstein Senior Analyst, US Biopharmaceuticals Courtney ... industry and painted the order as a blow against drugmakers. Eli Lilly (NYSE:LLY) recently announced the impressive results of its ...

Indianapolis-based Eli Lilly and Co. on Thursday posted 45% revenue growth in the first quarter of 2025 that topped Wall Street expectations, but stock prices tumbled more than 10% by midday after ...

Click here for access. * An analyst from Morgan Stanley persists with their Overweight rating on Eli Lilly, maintaining a target price of $1124. * In a positive move, an analyst from Goldman Sachs ...

Eli Lilly's stock ... BMO Capital Markets analyst Evan Seigerman said, per Reuters. Additionally, no liver-related safety signal was observed in the trial, Lilly said. Lilly's new pill can be ...

While arch rival Eli Lilly and Company ... a step function change for Lilly’s market leadership over NVO and its peers. Lilly management provided insights into the advantages of why the ...

Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) stock cut his price target on the pharmaceutical giant. Even though that ...